Farxiga and Entresto generics fall under $20

Heart drugs and diabetes drugs almost never become cheap overnight. But that is basically what the cash market is starting to signal for generic versions of Farxiga and Entresto. The headline number is real enough to grab attention — some online discount prices are now dramatically below the old brand-era price tags. The catch is that “cheap” in the drug market does not automatically mean “easy to get.” (goodrx.com) ### What drugs are we talking about? Farxiga is dapagliflozin — an SGLT2 inhibitor used for Type 2 diabetes, heart failure, and chronic kidney disease. Entresto is sacubitril/valsartan — a heart failure drug that became a standard therapy because it cuts hospitalizations and lowers the risk of death. These are not niche products. They are core medicines for common chronic conditions, which is why any real price break matters. (goodrx.com) ### Why is this happening now? The short version is generic entry. FDA approved first generic sacubitril/valsartan tablets in May 2024, and the first U.S. commercial launch followed in July 2025. FDA also approved first generic dapagliflozin tablets in April 2026. Approval is the gate, but launch and distribution are what start bending prices down in the real market. (fda.gov) ### Are the under-$20 numbers real? For Farxiga’s generic, yes — at least in the coupon-and-cash universe. GoodRx currently shows generic dapagliflozin 10 mg with a discount price as low as $11.23 for 30 tablets, versus an average retail price above $553 for the same generic and about $666 for brand Farxiga. That is a huge collapse, but it is a discounted cash price, not the average amount every patient will pay. (goodrx.com) ### What about Entresto? Entresto’s generic has dropped a lot too, but not quite into the same floor. GoodRx shows generic sacubitril/valsartan with discounts as low as $39.33 on one page, while another recent GoodRx explainer cites as low as $49.99 for 60 tablets of the top strength, against an average generic price around $544.88 and brand pricing near(goodrx.com)rly very expensive chronic meds are suddenly showing discount prices that look like ordinary generics. (goodrx.com) ### Why doesn’t every patient see those prices? Because the U.S. drug market has three layers — the list price, the insured price, and the coupon cash price. A patient may have insurance that prefers the brand, requires prior authorization, or forces step therapy before covering the generic. Pharmacies also have to stock the generic, and plans have to update formularies. (goodrx.com)xact NDC at that pharmacy without coverage rules getting in the way. (goodrx.com) ### Does this change the business model? Maybe. Once a molecule gets this cheap in cash channels, the competition shifts from pure price to convenience — refill handling, home delivery, adherence packaging, and direct-to-consumer pharmacy models. Cost Plus Drugs already lists both generic sacubitril/valsartan and generic dapagliflozin, which tells you these drugs are moving into the broader low-margin generic ecosystem. (costplusdrugs.com) ### What is the real takeaway? The real news is not just that generic Farxiga and generic Entresto exist. It is that the cash market is starting to price at least one of them like a true commodity, while the other is heading in the same direction. That is great for affordability on paper. But patients will only feel it if formularies, pharmacies, and prescribers stop acting like the brand era never ended.